{"schema_version":"secwatch.filing_event.v1","accession":"0001504337-23-000039","form_type":"8-K","ticker":"CLW","cik":"0001441236","company_name":"Clearwater Paper Corp","filed_at":"2023-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.088318+00:00","generated_at":"2026-06-09T05:46:25.866275+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Clearwater Paper Q3 adjusted net income up to $37M; tissue strength boosts Consumer Products","bullets":["Net sales of $520M, down 3% YoY; net income of $37M ($2.17 diluted EPS) vs $21M a year ago.","Adjusted EBITDA of $81M (15% margin) vs $77M in Q3 2022; Consumer Products segment EBITDA doubled to $46M.","Pulp & Paperboard segment sales fell 13% to $261M on lower volumes and prices; operating income $43M vs $64M.","Plans to redeem 2025 notes in Q4 using new term loan, cash, and ABL; repurchased $5M shares; net debt reduced $69M.","Company projects continued tissue strength into 2024 with gradual paperboard recovery; refinancing improves financial flexibility."],"urls":{"canonical":"https://secwatch.observer/filing/0001504337-23-000039","json":"https://secwatch.observer/filing/0001504337-23-000039.json","markdown":"https://secwatch.observer/filing/0001504337-23-000039.md","text":"https://secwatch.observer/filing/0001504337-23-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1441236/000150433723000039/0001504337-23-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1441236/000150433723000039/clw-20231030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T05:46:25.866275+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7437057a8f6da497ecd1a165d0640c628d6caef5","claim":"Clearwater Paper Corp reported the third quarter and nine months ended September 30, 2023 results: revenue Net sales of $520 million, net income Net income of $37 million, or $2.17 per diluted share, EPS $2.17 per diluted share.","evidence_excerpt":"months ended September 30, 2023. THIRD QUARTER HIGHLIGHTS • Outstanding performance driven by strong operational results and continued market strength in tissue • Net sales of $520 million, down 3% from the third quarter of last year • Net income of $37 million, or $2.17 per diluted share • Adjusted net income of $37 million, $6 million higher than the third","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1441236/000150433723000039/0001504337-23-000039-index.htm","confidence":0.97,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter and nine months ended September 30, 2023"},{"label":"Revenue","value":"Net sales of $520 million"},{"label":"Net income","value":"Net income of $37 million, or $2.17 per diluted share"},{"label":"EPS","value":"$2.17 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}